3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
5
Burkitt Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Ovarian Neoplasms
2
Lymphoma, Follicular
2
Leukemia, Biphenotypic, Acute
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Neoadjuvant Therapy
1
Myasthenia Gravis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, B-Cell
1
Heart Failure
1
Dendritic Cell Sarcoma, Interdigitating
1
Colorectal Neoplasms
1
Cardiotoxicity
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Adrenal Insufficiency
1
Interventions
fludarabine
6
efgartigimod alfa
6
Cyclophosphamide
6
ravulizumab
4
zilucoplan
2
telitacicept
2
rozanolixizumab
2
Prednisone
2
remibrutinib
1
iptacopan
1
inebilizumab
1
bu-zhong-yi-qi-tang
1
Walk Test
1
Tacrolimus
1
Steroids
1
Rituximab
1
Pyridostigmine Bromide
1
Prednisolone
1
Mycophenolic Acid
1
Diagnostic Self Evaluation
1
Cognitive Behavioral Therapy
1
Cladribine
1
Biomarkers
1
Azathioprine
1
Alleles
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Myasthenia Gravis
×
Prednisolone
×
Clear all
NCT07221838
2026-04-09
OCTAGON
Alexion Pharmaceuticals, Inc.
Phase 4
Recruiting
75 enrolled